DiaMedica Therapeutics Inc.

NasdaqCM:DMAC Stock Report

Market Cap: US$237.7m

DiaMedica Therapeutics Management

Management criteria checks 3/4

DiaMedica Therapeutics' CEO is Rick Pauls, appointed in Jan 2010, has a tenure of 19.75 years. total yearly compensation is $1.22M, comprised of 46.2% salary and 53.8% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $381.37K. The average tenure of the management team and the board of directors is 2.3 years and 5.7 years respectively.

Key information

Rick Pauls

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage46.2%
CEO tenure15yrs
CEO ownership0.2%
Management average tenure2.3yrs
Board average tenure5.7yrs

Recent management updates

Recent updates

Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation

Nov 23
Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation

Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation

May 16
Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation

We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

Jan 12
We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold

Jul 06

We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate

Jun 16
We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate

We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

Jan 04
We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

DiaMedica: Proven Stroke Drug In Asia, Headed To The U.S.

Nov 05

DiaMedica: Undercovered Stroke Drug Company With Decent Data

Jun 13

We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth

May 01
We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth

Could The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Ownership Structure Tell Us Something Useful?

Feb 13
Could The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Ownership Structure Tell Us Something Useful?

We're Not Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn

Jan 09
We're Not Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn

DiaMedica Therapeutics Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

CEO Compensation Analysis

How has Rick Pauls's remuneration changed compared to DiaMedica Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$22m

Jun 30 2024n/an/a

-US$20m

Mar 31 2024n/an/a

-US$19m

Dec 31 2023US$1mUS$562k

-US$19m

Sep 30 2023n/an/a

-US$18m

Jun 30 2023n/an/a

-US$17m

Mar 31 2023n/an/a

-US$15m

Dec 31 2022US$1mUS$523k

-US$14m

Sep 30 2022n/an/a

-US$13m

Jun 30 2022n/an/a

-US$14m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$1mUS$477k

-US$14m

Sep 30 2021n/an/a

-US$15m

Jun 30 2021n/an/a

-US$14m

Mar 31 2021n/an/a

-US$13m

Dec 31 2020US$878kUS$455k

-US$12m

Sep 30 2020n/an/a

-US$11m

Jun 30 2020n/an/a

-US$10m

Mar 31 2020n/an/a

-US$10m

Dec 31 2019US$2mUS$420k

-US$11m

Sep 30 2019n/an/a

-US$10m

Jun 30 2019n/an/a

-US$9m

Mar 31 2019n/an/a

-US$8m

Dec 31 2018US$734kUS$315k

-US$6m

Compensation vs Market: Rick's total compensation ($USD1.22M) is about average for companies of similar size in the US market ($USD1.38M).

Compensation vs Earnings: Rick's compensation has increased whilst the company is unprofitable.

CEO

Rick Pauls (53 yo)

15yrs

Tenure

US$1,215,161

Compensation

Mr. Dietrich John Pauls, also known as Rick, MBA has been Chief Executive Officer and President of DiaMedica Therapeutics Inc. since January 2010 and has been its Director since April 2005. Mr. Pauls was a...

Leadership Team

NamePositionTenureCompensationOwnership
Dietrich Pauls
President15yrsUS$1.22m0.16%
$ 381.4k
Scott Kellen
CFO & Corporate Secretary6.8yrsUS$632.22k0.076%
$ 179.5k
Ambarish Shah
Chief Technology Officer1.3yrsno datano data
Dominic Cundari
Chief Commercial Officer2.9yrsno data0.0066%
$ 15.6k
David Wambeke
Chief Business Officer1.8yrsno data1.23%
$ 2.9m
Lorianne Masuoka
Chief Medical Officerless than a yearno datano data

2.3yrs

Average Tenure

59yo

Average Age

Experienced Management: DMAC's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Dietrich Pauls
President19.8yrsUS$1.22m0.16%
$ 381.4k
James Parsons
Independent Director9.3yrsUS$97.18k0.0053%
$ 12.5k
R. Giuffre
Independent Director14.4yrsUS$90.93k0.76%
$ 1.8m
George L. Bakris
Member of Kidney Scientific Advisory Board5.7yrsno datano data
Richard Pilnik
Independent Chairman15.7yrsUS$133.98k0.33%
$ 786.5k
Glenn Chertow
Member of Kidney Scientific Advisory Board5.7yrsno datano data
Rajiv Agarwal
Member of Kidney Scientific Advisory Board5.7yrsno datano data
Philip Bath
Member of Stroke Advisory Board2yrsno datano data
Scott Kasner
Member of Stroke Clinical Advisory Boardno datano datano data
Charles Herzog
Member of Kidney Scientific Advisory Boardno datano datano data
John Volpi
Member of Stroke Clinical Advisory Boardno datano datano data
Aldo Peixoto
Member of Kidney Scientific Advisory Board5.7yrsno datano data

5.7yrs

Average Tenure

63yo

Average Age

Experienced Board: DMAC's board of directors are considered experienced (5.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 02:55
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

DiaMedica Therapeutics Inc. is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kyle BauserColliers Securities
Alexander NowakCraig-Hallum Capital Group LLC
Chase KnickerbockerCraig-Hallum Capital Group LLC